Loading...
For patients with metastatic colorectal cancer (CRC) who achieved a response or stable disease after chemotherapy, options include a chemotherapy holiday, continuation of combination chemotherapy and a targeted agent, or institution of fluorinated pyrimidine monotherapy with a targeted agent. In maintenance studies, progression-free survival (PFS) is consistently superior with therapy continuation than with a chemotherapy holiday. Maintenance studies also indicate superior PFS for continuation of a fluorinated pyrimidine and a targeted agent over a fluorinated pyrimidine alone.
Investigators now have reported results of the industry-supported, open-label, phase 3 ERMES maintenance trial for patients with RAS/BRAF wild-type metastatic CRC who…